{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:11:56Z","timestamp":1698750716247},"reference-count":25,"publisher":"Akademiai Kiado Zrt.","issue":"34","license":[{"start":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T00:00:00Z","timestamp":1629590400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,8,22]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic> Az adalimumab egy TNF\u03b1-g\u00e1tl\u00f3 monoklon\u00e1lis antitest;\n                    sz\u00e1mos indik\u00e1ci\u00f3ja k\u00f6z\u00fcl a nem fert\u0151z\u00e9ses eredet\u0171 intermedier, posterior \u00e9s\n                    panuveitisek kezel\u00e9s\u00e9ben is \u00e1ltal\u00e1nosan alkalmazhat\u00f3 k\u00e9sz\u00edtm\u00e9ny.\n                        <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> A feln\u0151ttkori nem fert\u0151z\u00e9ses eredet\u0171 uveitis\n                    miatt adalimumabkezel\u00e9st kap\u00f3 betegekkel szerzett tapasztalataink\n                    \u00f6sszefoglal\u00e1sa. <jats:italic>Betegek \u00e9s m\u00f3dszerek:<\/jats:italic> Retrospekt\u00edv\n                    esetsorozatban vizsg\u00e1ljuk a budapesti Uveitis Centrumban (a Semmelweis Egyetem\n                    Szem\u00e9szeti Klinik\u00e1j\u00e1nak Uveitis Ambulanci\u00e1j\u00e1n) 2018 \u00e9s 2020 k\u00f6z\u00f6tt adalimumabbal\n                    kezelt feln\u0151tt, nem fert\u0151z\u00e9ses eredet\u0171 uveitises eseteinket.\n                        <jats:italic>Eredm\u00e9nyek:<\/jats:italic> 13 beteget mutatunk be (8 n\u0151, 5 f\u00e9rfi),\n                    \u00e1tlag\u00e9letkor 45 (26\u201380) \u00e9v. Az adalimumabot 12 beteg Humira, 1 beteg Amgevita\n                    k\u00e9sz\u00edtm\u00e9ny form\u00e1j\u00e1ban kapja. Az uveitis eredete 2 esetben \u2019birdshot\u2019\n                    chorioretinitis, 2 esetben Beh\u00e7et-k\u00f3r, 1 esetben sarcoidosis, 3 esetben\n                    retinalis vasculitis, 1 esetben Vogt\u2013Koyanagi\u2013Harada-betegs\u00e9g volt, \u00e9s 4 esetben\n                    idiopathi\u00e1s eredet\u0171nek bizonyult. Az adalimumabkezel\u00e9st 7 betegn\u00e9l kellett\n                    elhagyni, els\u0151sorban ter\u00e1pi\u00e1s el\u00e9gtelens\u00e9g miatt, m\u00edg 6 betegn\u00e9l jelenleg is\n                    eredm\u00e9nyesen folyik a kezel\u00e9s. <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> Tapasztalataink\n                    alapj\u00e1n az adalimumab biztons\u00e1gos, kev\u00e9s mell\u00e9khat\u00e1ssal b\u00edr\u00f3, hat\u00e9kony kezel\u00e9s\n                    sz\u00e1mos uveitisform\u00e1ban \u00f6nmag\u00e1ban adva vagy kis d\u00f3zis\u00fa szteroiddal kieg\u00e9sz\u00edtve.\n                    Kor\u00e1bbi ter\u00e1pi\u00e1kra (szteroid, immunszuppresszi\u00f3) rezisztens esetekben is\n                    alkalmazhat\u00f3. A szem\u00e9szetben a sziszt\u00e9m\u00e1s biol\u00f3giai ter\u00e1pia, az adalimumab\n                    bevezet\u00e9se az uveitises betegek kezel\u00e9s\u00e9ben a l\u00e1t\u00f3\u00e9less\u00e9g meg\u0151rz\u00e9se\n                    szempontj\u00e1b\u00f3l sorsd\u00f6nt\u0151 jelent\u0151s\u00e9g\u0171. Orv Hetil. 2021; 162(34): 1370\u20131375.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold>\n                    <jats:italic>Introduction:<\/jats:italic> Adalimumab is a monoclonal antibody that inhibits\n                    TNF\u03b1 and among other indications it can be a systemic treatment in the\n                    non-infectious intermediate, posterior and panuveitis.\n                        <jats:italic>Objective:<\/jats:italic> To summarize our experience in patients\n                    receiving adalimumab for adult non-infectious uveitis. <jats:italic>Patients and\n                        methods:<\/jats:italic> We investigate our adult cases of non-infectious uveitis\n                    treated with adalimumab between 2018 and 2020 in a retrospective case series at\n                    the Uveitis Center in Budapest (Semmelweis University, Department of\n                    Ophthalmology, Uveitis Department). <jats:italic>Results:<\/jats:italic> We present 13\n                    patients (8 females, 5 males) with a mean age of 45 (26\u201380) years. Adalimumab is\n                    given to 12 patients as Humira and 1 patient as Amgevita. The etiology of\n                    uveitis was in 2 cases birdshot chorioretinitis, 2 Beh\u00e7et\u2019s disease, 1\n                    sarcoidosis, 3 retinal vasculitis, 1 Vogt\u2013Koyanagi\u2013Harada disease, and 4 of\n                    idiopathic origin. Adalimumab treatment had to be discontinued in 7 cases,\n                    mainly due to therapeutic insufficiency, while in 6 cases we are still\n                    successfully treating patients. <jats:italic>Conclusion:<\/jats:italic> According to our\n                    experience, adalimumab is a safe and effective treatment, with minimal side\n                    effect in many forms of uveitis alone, or in combination with a low-dose\n                    steroid. It can also be used in cases where traditional immunosuppressive\n                    therapies are ineffective. In ophthalmology, systemic biologic therapy,\n                    availability of adalimumab in the treatment of uveitis is crucial for\n                    maintaining visual acuity at affected patients. Orv Hetil. 2021; 162(34):\n                    1370\u20131375.<\/jats:p>","DOI":"10.1556\/650.2021.32188","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:07:06Z","timestamp":1630404426000},"page":"1370-1375","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":1,"title":["A TNF\u03b1-g\u00e1tl\u00f3 szem\u00e9szeti alkalmaz\u00e1sa: adalimumabkezel\u00e9s uveitisben"],"prefix":"10.1556","volume":"162","author":[{"given":"Zsuzsanna","family":"G\u00e9hl","sequence":"first","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i \u00fat 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Szepessy","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i \u00fat 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n Zsolt","family":"Nagy","sequence":"additional","affiliation":[{"name":"1 Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Szem\u00e9szeti Klinika, Budapest, \u00dcll\u0151i \u00fat 26., 1085"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12348-018-0148-5","article-title":"Epidemiology of uveitis in a US population-based study","volume":"8","author":"1 Gonz\u00e1lez","year":"2018","unstructured":"1 Gonz\u00e1lez MM, Solano MM, Porco TC, et al. Epidemiology of uveitis in a US population-based study. J Ophthalmic Inflamm Infect. 2018; 8: 6.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"2 Durrani","year":"2004","unstructured":"2 Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004; 88: 1159-1162.","journal-title":"Br J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the uveitides","volume":"125","author":"3 Jabs","year":"2018","unstructured":"3 Jabs DA. Immunosuppression for the uveitides. Ophthalmology 2018; 125: 193-202.","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4 Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140: 509-516.","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/ICU.0000000000000562","article-title":"Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics","volume":"30","author":"5 Thomas","year":"2019","unstructured":"5 Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2019; 30: 138-150.","journal-title":"Curr Opin Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"6 Jabs","year":"2000","unstructured":"6 Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000; 130: 492-513.","journal-title":"Am J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009; 148: 500-509.e2.","DOI":"10.1016\/j.ajo.2009.05.008"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8 Gangaputra S, Newcomb CW, Liesegang TL, et al. Systemic immunosuppressive therapy for eye diseases cohort study. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009; 116: 2188-2198.e1.","DOI":"10.1016\/j.ophtha.2009.04.020"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010; 149: 423-432.e2.","DOI":"10.1016\/j.ajo.2009.09.026"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"10 Ka\u00e7maz","year":"2010","unstructured":"10 Ka\u00e7maz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010; 117: 576-584.","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study","volume":"15","author":"11 Kempen","year":"2008","unstructured":"11 Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008; 15: 47-55.","journal-title":"Ophthalmic Epidemiol"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12 Writing Comittee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group, Kempen JH, Altaweel MM, Holbrook JT, et al. Association between long-lasting intravitreous fluocinolone acetonide implant vs. systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA 2017; 317: 1993-2005.","DOI":"10.1001\/jama.2017.5103"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/jir.2011.0042","article-title":"Cytokines in autoimmune uveitis","volume":"31","author":"Horai R","year":"2011","unstructured":"13 Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res. 2011; 31: 733-744.","journal-title":"J Interferon Cytokine Res"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14 Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; 121: 785-796.e3.","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"15 Jaffe","year":"2016","unstructured":"15 Jaffe GJ, Dick AD, Br\u00e9zin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016; 375: 932-943.","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16 Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; 388: 1183-1192. [Erratum: Lancet 2016; 388: 1160.]","DOI":"10.1016\/S0140-6736(16)31339-3"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"17 Suhler","year":"2018","unstructured":"17 Suhler EB, Ad\u00e1n A, Br\u00e9zin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 2018; 125: 1075-1087.","journal-title":"Ophthalmology"},{"key":"ref17","unstructured":"18 AbbVie Ltd. Humira (adalimumab). EU summary of product characteristics, 2016. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf [accessed: January 25, 2021]."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","author":"Cordero-Coma M","year":"2015","unstructured":"19 Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-\u03b1 therapy in uveitis. Surv Ophthalmol. 2015; 60: 575-589.","journal-title":"Surv Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 Beny\u00f3 F, Farkas A, Horv\u00e1th H, et al. Systemic biological treatment in ophthalmology. [Biol\u00f3giai ter\u00e1pia sziszt\u00e9m\u00e1s alkalmaz\u00e1sa a szem\u00e9szetben.] Orv Hetil. 2019; 160: 1744-1750. [Hungarian]","DOI":"10.1556\/650.2019.31552"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"21 Rudwaleit","year":"2009","unstructured":"21 Rudwaleit M, R\u00f8devand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009; 68: 696-701.","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/09273948.2016.1158277","article-title":"Evolving \"diagnostic\" criteria for axial spondyloarthritis in the context of anterior uveitis","volume":"24","author":"22 Rosenbaum","year":"2016","unstructured":"22 Rosenbaum JT. Evolving \"diagnostic\" criteria for axial spondyloarthritis in the context of anterior uveitis. Ocul Immunol Inflamm. 2016; 24: 445-449.","journal-title":"Ocul Immunol Inflamm"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"23 Markomichelakis","year":"2004","unstructured":"23 Markomichelakis NN, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004; 138: 648-650.","journal-title":"Am J Ophthalmol"},{"key":"ref23","unstructured":"24 Fodor M, Poly\u00e1k-P\u00e1sztor D, P\u00e1sztor O, et al. The impact of adalimumab in the treatment of non-infectious uveitis. [Az adalimumab jelent\u0151s\u00e9ge a nem fert\u0151z\u00e9ses eredet\u0171 uveitisek kezel\u00e9s\u00e9ben.] Szem\u00e9szet 2020; 157: 62-68. [Hungarian]"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ophtha.2019.08.031","article-title":"Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"127","author":"25 Al-Janabi","year":"2020","unstructured":"25 Al-Janabi A, El Nokrashy A, Sharief L, at al. Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 2020; 127: 410-416.","journal-title":"Ophthalmology"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/34\/article-p1370.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/34\/article-p1370.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:57:53Z","timestamp":1698659873000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/34\/article-p1370.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,22]]},"references-count":25,"journal-issue":{"issue":"34"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32188","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,22]]}}}